<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308448</url>
  </required_header>
  <id_info>
    <org_study_id>IUMS 96-03-124-31806</org_study_id>
    <nct_id>NCT03308448</nct_id>
  </id_info>
  <brief_title>Traumatic Optic Neuropathy Treatment Trial 2</brief_title>
  <acronym>TONTT-2</acronym>
  <official_title>Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tabriz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After introducing intravenous erythropoietin (EPO) as an option for treatment of patients
      with indirect traumatic optic neuropathy in 2011 and publishing non inferiority trial in
      Oct.2017), TONTT2 is aiming to find out the best dose and timing of EPO administration in
      this group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with TON will be visited. After being eligible to enter the study and obtaining
      informed consent, they will be randomly assigned into 3 groups of different total dose of
      intravenous administration of EPO to which patients and outcome assessors will be masked.
      They will be assessed at different follow up time periods with the last follow up of at least
      3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 treatment groups of patients with TON will receive different total dose of EPO.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants are unaware of the dose of EPO. Outcome assessors are masked to the dose of EPO</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean LogMAR Best corrected visual acuity (BCVA) from 20/20 to no light perception (NLP) as assessed by Snellen visual acuity chart and analyzed based on mean LogMAR change.</measure>
    <time_frame>Before treatment and on day 1,2,3, 7, 30, and 90 days after the treatment and through study completion, an average of 24 months</time_frame>
    <description>Best corrected Visual acuity is measured (Snellen eye chart) and recorded as 20/20-20/25, 20/30, 20/40, 20, 50, 20/70, 20/100, 20/200 and then counting finger (CF), hand motion (HM), light perception (LP), and no light perception (NLP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Log Unit of Relative afferent pupillary defect (RAPD) from 0.3 to 1.8 log unit as assessed by Neutral density filter</measure>
    <time_frame>Before treatment and on day 1,2,3, 7, 30, and 90 days after the treatment and through study completion, an average of 24 months</time_frame>
    <description>RAPD will be measured based on six log unit of 0.3, 0.6, 0.9, 1.2, 1.5,and 1.8 in which the higher the number the higher the severity score of RAPD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean number of visible color plates in Color vision test book. It is from 24/24 to 0/24 as assessed by Ishihara 24-plate color test book</measure>
    <time_frame>Before treatment and on day 1,2,3, 7, 30, and 90 days after the treatment and through study completion, an average of 24 months</time_frame>
    <description>Using Ishihara 24-plate color vision test book, the color vision will be recorded as a fraction of 24 plates; e.g. 10/24. Patients with lower than 20/200 vision will have 0/24 since they can not read the color plates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment related adverse effects as assessed by history taking (change in mood, vertigo, faint), examination (blood pressure) and blood tests (CBC, BUN, Cr., K, Na, PT, PTT, INR, Ca., Ph)</measure>
    <time_frame>before treatment and on day 1, 2 and 3 after treatment.</time_frame>
    <description>history taking (change in mood, vertigo, faint), examination (blood pressure) and blood tests (CBC, BUN, Cr., K, Na, PT, PTT, INR, Ca., Ph) will be performed before treatment and on day 1, 2 and 3 after treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Traumatic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human erythropoietin</intervention_name>
    <description>Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>EPO, Eprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Having indirect traumatic optic neuropathy(with normal eye and fundus exam)

          2. Trauma to treatment interval of 3 weeks and less

          3. Age of 7 years and more

        Exclusion Criteria:

          1. Direct optic neuropathy,

          2. Glaucoma,

          3. Any retinopathy

          4. Globe laceration

          5. Age under 7

          6. Hypertension,

          7. Polycythemia,

          8. Creatinin more than 3 mg/dl,

          9. Sensitivity to EPO

         10. Patients who have received any other form of treatment for their traumatic optic
             neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohsen B Kashkouli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Iran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohsen B Kashkouli, MD</last_name>
    <phone>0098 912 1777003</phone>
    <email>mkashkouli2@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahya Ghazizadeh, MD</last_name>
    <phone>0098 912 4777989</phone>
    <email>mahyagh1990@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Iran University of Medical Sciences</name>
      <address>
        <city>TehrƒÅn</city>
        <state>Tehran</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohsen B Kashkouli, MD</last_name>
      <phone>0098 912 1777003</phone>
      <email>mkashkouli2@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mashhad University of Medical Sciences</name>
      <address>
        <city>Mashhad</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Etezad-Razavi, MD</last_name>
      <phone>0098 915 5199624</phone>
      <email>etezadm@mums.ac.ir</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad B Abtahi, MD</last_name>
      <phone>0098917 7176970</phone>
      <email>begherabtahi@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tabriz University of Medical Sciences</name>
      <address>
        <city>Tabriz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dima Andalib</last_name>
      <phone>0098914 3111855</phone>
      <email>dima1366@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farzad Pakdel, MD</last_name>
      <phone>00989123701876</phone>
      <email>fapakdel@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Kashkouli MB, Pakdel F, Sanjari MS, Haghighi A, Nojomi M, Homaee MH, Heirati A. Erythropoietin: a novel treatment for traumatic optic neuropathy-a pilot study. Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):731-6. doi: 10.1007/s00417-010-1534-3. Epub 2010 Oct 2.</citation>
    <PMID>20890611</PMID>
  </reference>
  <reference>
    <citation>Entezari M, Esmaeili M, Yaseri M. A pilot study of the effect of intravenous erythropoetin on improvement of visual function in patients with recent indirect traumatic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1309-13. doi: 10.1007/s00417-014-2691-6. Epub 2014 Jul 2.</citation>
    <PMID>24986593</PMID>
  </reference>
  <reference>
    <citation>Kashkouli MB, Yousefi S, Nojomi M, Sanjari MS, Pakdel F, Entezari M, Etezad-Razavi M, Razeghinejad MR, Esmaeli M, Shafiee M, Bagheri M. Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi-experimental trial. Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):209-218. doi: 10.1007/s00417-017-3816-5. Epub 2017 Oct 6.</citation>
    <PMID>28986670</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>January 27, 2018</last_update_submitted>
  <last_update_submitted_qc>January 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Traumatic optic neuropathy</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>EPO</keyword>
  <keyword>Eprex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Nerve Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD information will be available at the end of the study after submitting for publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

